Competitive ELISA, Immobilized antigen
The Urine CartiLaps® (CTX-II) EIA detects degradation products of C-terminal telopeptides of type II collagen. It is intended for in-vitro diagnostic use as an indication of degradation of cartilage and may be used as an aid for:
- Quantitative assessment of disease activity (structural damage of articular cartilage) in patients with RA and OA.
- Prognosis of disease activity in patients with RA and OA, and early assessment of long-term effect of therapy in patients with RA.
Disruption of the structural integrity of cartilage is the major histological finding in osteoarthritis and rheumatoid arthritis. Type II collagen is the major organic constituent of cartilage. Fragments of type II collagen (CTX-II) are being released into circulation and subsequently secreted into urine following degradation of cartilage. In urine, the CTX-II fragments can be quantified by Urine CartiLaps® (CTX-II) EIA. The Urine CartiLaps® (CTX-II) EIA has been reported to be useful in prediction of the progression of osteoarthritis (Reijman et al., Garnero et al), and in other clinical (Rotterud) and pre-clinical investigations.
Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).
Limit of Detection
The kits are CE-IVD certified and intended for professional use.